中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

原发性胆汁性胆管炎合并胃弥漫性大B细胞淋巴瘤1例报告

冯丽娜 黄剑洁 涂芷馨 王妍 张晓雪 马博 温晓玉 金清龙

引用本文:
Citation:

原发性胆汁性胆管炎合并胃弥漫性大B细胞淋巴瘤1例报告

DOI: 10.3969/j.issn.1001-5256.2021.03.034
基金项目: 

国家自然科学基金 (81270484)

利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:冯丽娜、黄剑洁负责课题设计,资料分析,撰写论文;涂芷馨、王妍、张晓雪、马博参与收集数据,修改论文;温晓玉、金清龙负责拟定写作思路,指导撰写文章并最后定稿。
详细信息
    作者简介:

    冯丽娜(1994—),女,主要从事消化内科疾病研究

    通信作者:

    金清龙,jinql2016@163.com

  • 中图分类号: R576

Primary biliary cholangitis with gastric diffuse large B-cell lymphoma: A case report

  • 图  1  胃镜和病理组织染色结果

    注:a,胃体中下部、胃窦、胃角见一巨大环周不规则肿物;b,肿瘤细胞弥漫分布(HE染色,×400);c,Ki-67阳性(免疫组化,×400);d,CD20(+)(免疫组化,×400)。

  • [1] YAMAGIWA S, KAMIMURA H, TAKAMURA M, et al. Autoantibodies in primary biliary cirrhosis: Recent progress in research on the pathogenetic and clinical significance[J]. World J Gastroenterol, 2014, 20(10): 2606-2612. DOI: 10.3748/wjg.v20.i10.2606
    [2] KOUMATI E, PALASSOPOULOU M, MATSOUKA P, et al. Multiple autoimmune propensity and B-non-Hodgkin lymphoma: Cause or effect?[J]. Autoimmune Dis, 2011, 2011: 841325. http://europepmc.org/articles/PMC3112510/
    [3] SMEDBY KE, HJALGRIM H, ASKLING J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype[J]. J Natl Cancer Inst, 2006, 98(1): 51-60. DOI: 10.1093/jnci/djj004
    [4] ALEXANDER DD, MINK PJ, ADAMI HO, et al. The non-Hodgkin lymphomas: A review of the epidemiologic literature[J]. Int J Cancer, 2007, 120(Suppl 12): 1-39. http://www.ncbi.nlm.nih.gov/pubmed/17405121
    [5] GOLDIN LR, LANDGREN O. Autoimmunity and lymphomagenesis[J]. Int J Cancer, 2009, 124(7): 1497-1502. DOI: 10.1002/ijc.24141
    [6] FLOREANI A, SPINAZZÈ A, CABALLERIA L, et al. Extrahepatic malignancies in primary biliary cirrhosis: A comparative study at two European centers[J]. Clin Rev Allergy Immunol, 2015, 48(2-3): 254-262. DOI: 10.1007/s12016-014-8446-7
    [7] KANELLOPOULOU T, ALEXOPOULOU A, KONTOPIDOU FN, et al. Development of non-Hodgkin's lymphoma in a patient with primary biliary cirrhosis: A case report and review of the literature[J]. Ann Gastroenterol, 2011, 24(2): 125-128. http://pubmedcentralcanada.ca/pmcc/articles/PMC3959296/
    [8] PANJALA C, TALWALKAR JA, LINDOR KD. Risk of lymphoma in primary biliary cirrhosis[J]. Clin Gastroenterol Hepatol, 2007, 5(6): 761-764. DOI: 10.1016/j.cgh.2007.02.020
    [9] TIAN H. Rheumatic and skin manifestations associated with autoimmune liver diseases[J]. J Clin Hepatol, 2018, 34(9): 2021-2026. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2018.09.041

    田辉. 自身免疫性肝病相关性风湿病样及皮肤表现[J]. 临床肝胆病杂志, 2018, 34(9): 2021-2026. DOI: 10.3969/j.issn.1001-5256.2018.09.041
    [10] ZHANG W, FENG S, YAN S, et al. Incidence of malignancy in primary Sjogren's syndrome in a Chinese cohort[J]. Rheumatology (Oxford), 2010, 49(3): 571-577. DOI: 10.1093/rheumatology/kep404
    [11] GOODNOW CC. Multistep pathogenesis of autoimmune disease[J]. Cell, 2007, 130(1): 25-35. DOI: 10.1016/j.cell.2007.06.033
    [12] JARDIN F. Development of autoimmunity in lymphoma[J]. Expert Rev Clin Immunol, 2008, 4(2): 247-266. DOI: 10.1586/1744666X.4.2.247
    [13] MYERS RP, SWAIN MG, LEE SS, et al. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid[J]. Am J Gastroenterol, 2013, 108(6): 933-941. DOI: 10.1038/ajg.2013.51
    [14] XIA Y, ZHOU ZW. Treatment of primary gastric lymphoma[J]. Chin J Gastrointestinal Surg, 2017, 20(11): 1227-1230. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL200919019.htm

    夏奕, 周志伟. 原发性胃淋巴瘤的治疗策略[J]. 中华胃肠外科杂志, 2017, 20(11): 1227-1230. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL200919019.htm
    [15] TSUDA M, MORITOKI Y, LIAN ZX, et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid[J]. Hepatology, 2012, 55(2): 512-521. DOI: 10.1002/hep.24748
    [16] KHANNA A, JOPSON L, HOWEL D, et al. Rituximab is ineffective for treatment of fatigue in primary biliary cholangitis: A phase 2 randomized controlled trial[J]. Hepatology, 2019, 70(5): 1646-1657. DOI: 10.1002/hep.30099
    [17] DHIRAPONG A, LLEO A, YANG GX, et al. B cell depletion therapy exacerbates murine primary biliary cirrhosis[J]. Hepatology, 2011, 53(2): 527-535. DOI: 10.1002/hep.24044
    [18] YIN YF, ZHANG X. B cell depletion in treating primary biliary cirrhosis: Pros and cons[J]. World J Gastroenterol, 2012, 18(30): 3938-3940. DOI: 10.3748/wjg.v18.i30.3938
    [19] TAJIRI K, TSUNEYAMA K, MIYAZONO T, et al. A case of primary biliary cirrhosis that progressed rapidly after treatment involving rituximab[J]. Case Rep Gastroenterol, 2013, 7(1): 195-201. DOI: 10.1159/000351173
  • 加载中
图(1)
计量
  • 文章访问数:  337
  • HTML全文浏览量:  112
  • PDF下载量:  29
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-08-02
  • 录用日期:  2020-10-12
  • 出版日期:  2021-03-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回